viewArix Bioscience PLC

Arix Bioscience appoints industry heavyweight to board

Amin has 25 years experience and is currently chief executive at GMP-Orphan and venture partner at Advent Life Sciences

Arix Bioscience PLC - Arix Bioscience appoints industry-heavyweight to board

Arix Bioscience PLC (LON:ARIX) has appointed industry-heavyweight Naseem Amin to the board as non-executive director with immediate effect.

Amin, who was previously chief scientific officer at Smith & Nephew PLC (LON:SN) and senior vice president of business development Biogen Inc (NASDAQ:BIIB), will also be a member of the remuneration committee.

READ: Arix Bioscience notes portfolio company Iterum releases topline results for a Phase 3 trial of antibiotic

Amin is currently chief executive at GMP-Orphan and venture partner at Advent Life Sciences, following a 25-year career in the life sciences industry.

Arix NED Franz Humer is retiring from the board at the same time.

“We are very pleased to have Naseem join the board,” Jonathan Peacock, chairman at Arix, said in a release.

“His broad experience in life sciences, corporate development and venture capital, coupled with his strong industry network, will be invaluable in guiding Arix’s vision of building a broad portfolio of innovative young biotech companies to deliver important new therapies for patients and substantial value to our investors.”

Quick facts: Arix Bioscience PLC

Price: 59.74 GBX

Market: LSE
Market Cap: £80.98 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Arix Bioscience PLC named herein, including the promotion by the Company of Arix Bioscience PLC in any Content on the Site, the Company...



Aura Biosciences reports positive clinical data on its eye cancer treatment...

Aura Biosciences Inc CEO Elisabet de los Pinos tells Proactive Investors the biotech has reported positive clinical data from its Phase 1b/2 clinical trial evaluating the safety and efficacy of light- activated AU-011, its lead product candidate for the treatment of choroidal melanoma, a type...

on 11/06/2018

2 min read